This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Auvelity

First FDA-approved oral rapid-onset antidepressant (2022).

Aliases (3)

AXS-05 · dextromethorphan-bupropion · DXM/BUP

TYPICAL DOSE

—

ROUTE

—

CYCLE

—

STORAGE

—

Overview

What is Auvelity?

First FDA-approved oral rapid-onset antidepressant (2022). DXM + bupropion combination; bupropion's CYP2D6 inhibition keeps DXM at antidepressant levels. Week-1 response vs week-4-6 for SSRIs. WATCH-LIST for Dylan; relevant if mood support ever needed.

What to Expect

Week 1
Tolerability and dose-response.
Week 2-4
Early effect window.
Week 4-8
Peak benefit assessment.
Week 8+
Cycle decision point.

Was this helpful?

Your feedback shapes what we research deeper.

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…

✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸

Loading…

Continue: Extended research →

Our verdict, decision matrix, deep dives, controversies, sources

Related compounds

Cross-referenced from Auvelity

NDRI (norepinephrine + dopamine reuptake inhibitor) + nicotinic α4β2 antagonist (atypical antidepressant)

Arylcyclohexylamine dissociative anesthetic / non-competitive open-channel NMDA receptor antagonist with sigma-1 agonism, opioid (μ/κ/δ) low-affinity binding, and downstream glutamate-burst → AMPA → BDNF → mTORC1 plasticity cascade

SSRI (selective serotonin reuptake inhibitor)

SSRI (S-enantiomer of citalopram)

Multimodal serotonergic antidepressant (SERT inhibition + 5-HT3 antagonist + 5-HT7 antagonist + 5-HT1B partial agonist + 5-HT1A agonist) — not a "pure" SSRI

Atypical antidepressant (Servier 1983) — functionally a μ-opioid + δ-opioid agonist